NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...

NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...

(RTTNews) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.

Glatiramer acetate injection is a treatment for multiple sclerosis. ScinoPharm Taiwan pointed out that since its approval in 1996, glatiramer acetate has been recognized as one of the most challenging ...

Since its approval in 1996, Glatiramer Acetate (GA) has been recognized as one of the most challenging complex synthetic polypeptides globally. To address the unique nature of such products, the U.S.

TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) ...

Shares of Zenas Biopharma Inc. (NASDAQ:ZBIO) were trading at $15.04, down $19.46, or 56%, on positive results from the phase III Indigo trial with obexelimab in immunoglobulin G4-related disease (IgG4 ...

AHMEDABAD, India--(BUSINESS WIRE)--#ChemiSpA--Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States ...

Most of the patients in these reported cases experienced anaphylaxis within 1 hour after injection. Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug ...